fluorodopa f 18 has been researched along with Astrocytoma, Grade IV in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Brinkmann, DH; Herman, MG; Hunt, CH; Kemp, BJ; Laack, NN; Lowe, V; Pafundi, DH; Qian, J | 1 |
| Anderson, SK; Brinkmann, D; Brown, P; Hunt, C; Kabat, B; Kaufmann, T; Kemp, B; Kizilbash, S; Laack, NN; Lowe, V; Pafundi, D; Ruff, M; Sarkaria, J; Seaberg, M; Uhm, J; Vogen, D; Wan Chan Tseung, HS; Yan, E; Zakhary, M; Zhang, Y | 1 |
| Benard, F; Chan, EK; Cheung, A; Hsu, F; Kosztyla, R; Ma, R; Moiseenko, V; Nichol, A; Wilson, D; Zhang, S | 1 |
| Afshar-Oromieh, A; Combs, SE; Debus, J; Giesel, FL; Haberkorn, U; Kratochwil, C; Leotta, K; Rieken, S | 1 |
| Benz, MR; Buck, AK; Chen, W; Cloughesy, T; Czernin, J; Herrmann, K; Lai, A; Phelps, ME; Pomykala, KL | 1 |
| Bourgeat, P; Coulthard, A; Crozier, S; Daglish, M; Dowson, N; Fay, M; MacFarlane, D; Rose, S; Salvado, O; Smith, J; Thomas, P; Winter, C | 1 |
1 trial(s) available for fluorodopa f 18 and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Initial Results of a Phase 2 Trial of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition; Confidence Intervals; Dihydroxyphenylalanine; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Methylation; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Positron-Emission Tomography; Progression-Free Survival; Prospective Studies; Quality of Life; Radiopharmaceuticals; Radiotherapy, Image-Guided; Temozolomide; Young Adult | 2021 |
5 other study(ies) available for fluorodopa f 18 and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Prediction of MGMT Status for Glioblastoma Patients Using Radiomics Feature Extraction From
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Brain Neoplasms; Dihydroxyphenylalanine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Machine Learning; Male; Methylation; Middle Aged; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; Tumor Suppressor Proteins; Young Adult | 2020 |
High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Contrast Media; Dihydroxyphenylalanine; Female; Fluorine Radioisotopes; Gadolinium; Glioblastoma; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Observer Variation; Oligodendroglioma; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Sensitivity and Specificity; Tumor Burden; Young Adult | 2013 |
Intra-individual comparison of ¹⁸F-FET and ¹⁸F-DOPA in PET imaging of recurrent brain tumors.
Topics: Astrocytoma; Brain Neoplasms; Dihydroxyphenylalanine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Positron-Emission Tomography; Tyrosine | 2014 |
Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Dihydroxyphenylalanine; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed; Young Adult | 2014 |
Joint factor and kinetic analysis of dynamic FDOPA PET scans of brain cancer patients.
Topics: Algorithms; Brain Neoplasms; Computer Simulation; Dihydroxyphenylalanine; Factor Analysis, Statistical; Glioblastoma; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Kinetics; Metabolic Clearance Rate; Models, Biological; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2010 |